STANLEY MONCRIEF LEMON, M.D.
Osteopathic Medicine in Chapel Hill, NC
License number
North Carolina 20033
Category
Osteopathic Medicine
Type
Infectious Disease
License number
North Carolina L5636
Category
Osteopathic Medicine
Type
Infectious Disease
Address
Address
8 NORTH Carolina At Chapel Hl, Chapel Hill, NC 27599
Phone
(919) 843-1848
(919) 843-7240 (Fax)
(919) 843-7240 (Fax)
Personal information
See more information about STANLEY MONCRIEF LEMON at radaris.comName
Address
Phone
101 Bolinas Way, Chapel Hill, NC 27517
101 Pine Ln, Chapel Hill, NC 27514
101 Bolinas Way, Chapel Hill, NC 27517
Professional information
Stanley Moncrief Lemon, Chapel Hill NC
Specialties:
Infectious Disease Specialist
Address:
130 Mason Farm Road, Chapel Hill, NC 27599
Education:
University of Rochester, School of Medicine and Dentistry - Doctor of Medicine
North Carolina Children's Hospital - Fellowship - Infectious Disease (Internal Medicine)
North Carolina Children's Hospital - Residency - Family Medicine
North Carolina Children's Hospital - Fellowship - Infectious Disease (Internal Medicine)
North Carolina Children's Hospital - Residency - Family Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Infectious Disease (Internal Medicine)
Dr. Stanley M Lemon, Chapel Hill NC - MD (Doctor of Medicine)
Specialties:
Infectious Disease Medicine
Address:
8.034 Burnett-Womack Cb SUITE 7292, Chapel Hill 27599
Certifications:
Infectious Disease, 1978, Internal Medicine, 1975
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Rochester
Graduated: 1972
University Of North Carolina Hospitals
University of Rochester
Graduated: 1972
University Of North Carolina Hospitals
Stanley Moncrief Lemon, Chapel Hill NC
Specialties:
Internal Medicine, Infectious Disease
Work:
UNC Physicians and Associates Group
101 Manning Dr, Chapel Hill, NC 27514
101 Manning Dr, Chapel Hill, NC 27514
Education:
University of Rochester(1972)
Hepatitis A Virus Deletion Mutants And Vaccine Formulations Containing The Same
US Patent:
6136322, Oct 24, 2000
Filed:
Jun 15, 1998
Appl. No.:
9/094919
Inventors:
Stanley M. Lemon - Chapel Hill NC
David R. Shaffer - Chapel Hill NC
David R. Shaffer - Chapel Hill NC
Assignee:
The University of North Carolina at Chapel Hill - Chapel Hill NC
International Classification:
C12N 1551
US Classification:
4242261
Abstract:
Disclosed are live hepatitis A virus deletion mutants having a deletion mutation in the 5' nontranslated region of the viral genome. The deletion mutation may be selected from the group consisting of (a) pY1 deletion mutations that cause the virus to retain the ability to replicate in monkey kidney cells; and (b) deletion mutations between nucleotides 140 and 144 that render the virus temperature sensitive. Advantageously, the deletion mutation may be an attenuating mutation. Pharmaceutical formulations containing such viruses are disclosed, along with the use thereof to produce antibodies useful for diagnostic purposes and for imparting protective immunity against hepatitis A virus.
Hepatitis A Virus Deletion Mutants And Vaccine Formulations Containing The Same
US Patent:
5766906, Jun 16, 1998
Filed:
Jul 11, 1994
Appl. No.:
8/273594
Inventors:
Stanley M. Lemon - Chapel Hill NC
David R. Shaffer - Chapel Hill NC
David R. Shaffer - Chapel Hill NC
Assignee:
The University of North Carolina at Chapel Hill - Chapel Hill NC
International Classification:
C12N 1551
US Classification:
4351733
Abstract:
Disclosed are live hepatitis A virus deletion mutants having a deletion mutation in the 5' nontranslated region of the viral genome. The deletion mutation may be selected from the group consisting of (a) pY1 deletion mutations that cause the virus to retain the ability to replicate in monkey kidney cells; and (b) deletion mutations between nucleotides 140 and 144 that render the virus temperature sensitive. Advantageously, the deletion mutation may be an attenuating mutation. Pharmaceutical formulations containing such viruses are disclosed, along with the use thereof to produce antibodies useful for diagnostic purposes and for imparting protective immunity against hepatitis A virus.